The Experts below are selected from a list of 9888 Experts worldwide ranked by ideXlab platform
Morgan Roupret - One of the best experts on this subject based on the ideXlab platform.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, R Sylvester, Richard Zigeuner, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) guidelines panel on upper Urinary Tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, Richard Zigeuner, Richard Sylvester, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; ureteroscopy; nephroureterectomy; adjuvant treatment; instillation; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing number of retrospective articles in UTUC. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification, as well as for radical and conservative treatment; prognostic factors are also discussed. A single postoperative dose of intravesical mitomycin after radical nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumours and two functional kidneys. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis; appropriate diagnosis and management is most important. We present recommendations based on current evidence for optimal management.
-
the role of chemotherapy in the treatment of urothelial cell carcinoma of the upper Urinary Tract uut ucc
Urologic Oncology-seminars and Original Investigations, 2013Co-Authors: Francois Audenet, Olivier Cussenot, David R Yates, Morgan RoupretAbstract:AbsTract Objective Urothelial cell carcinoma of the upper Urinary Tract (UUT-UCC) is a rare, aggressive urologic Cancer with a propensity for multifocality, local recurrence, and metastasis. This review highlights the main chemotherapy regimens available for UUT-UCCs based on the recent literature. Materials and methods Data on urothelial malignancies and UUT-UCCs management in the literature were searched using MEDLINE and by matching the following key words: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract; carcinoma; transitional cell; renal pelvis; ureter; bladder Cancer; chemotherapy; nephroureterectomy; adjuvant treatment; neoadjuvant treatment; recurrence; risk factors; and survival. Results No evidence level 1 information from prospective randomized trials was available. Because of its many similarities with bladder urothelial carcinomas, chemotherapy with a cisplatin-containing regimen is often proposed in patients with metastatic or locally advanced disease. Most teams have proposed a neoadjuvant or an adjuvant treatment based either on the combination of methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) or on gemcitabine/cisplatin (GC). These regimens have been shown to prolong survival moderately. All recent studies have included limited numbers of patients and have reported poor patient outcomes after both neoadjuvant and adjuvant chemotherapy. Regarding metastatic UUT-UCCs, vinflunine has demonstrated moderate activity in these patients with a manageable toxicity. Interestingly, specific molecular markers [microsatellite instability (MSI), E-cadherin, HIF-1α, and RNA levels of the telomerase gene] can provide useful information that can help diagnose and determine patient prognosis in patients with UUT-UCC. Conclusion Chemotherapy with a cisplatin-containing regimen is often proposed in patients with metastatic or locally advanced disease. However, there is no strong evidence that chemotherapy is effective due to the rarity of the disease and the lack of data in the current literature. Thus, physicians must take into account the specific clinical characteristics of each individual patient with regard to renal function, medical comorbidities, tumor location, grade, and stage, and molecular marker status when determining the optimal treatment regimen for their patients. The ongoing identification of the oncologic mechanisms of this type of Cancer might pave the way for the development of specific treatments that are targeted to the characteristics of each patient's tumor in the future.
-
european guidelines for the diagnosis and management of upper Urinary Tract urothelial cell carcinomas 2011 update
Actas Urologicas Espanolas, 2012Co-Authors: Morgan Roupret, Richard Zigeuner, Joan Palou, Andreas Boehle, E Kaasinen, Richard Sylvester, Marko Babjuk, Willem OosterlinckAbstract:AbsTract Context The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper Urinary Tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: Urinary Tract Cancer, urothelial carcinomas, upper Urinary Tract, carcinoma, transitional cell, renal pelvis, ureter, bladder Cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references. Evidence synthesis There is a lack of data in the current literature to provide strong recommendations due to the rarity of the disease. A number of recent multicentre studies are now available, whereas earlier publications were based only on limited populations. However, most of these studies have been retrospective analyses. The 2009 TNM classification is recommended. Recommendations are given for diagnosis as well as for radical and conservative treatment; prognostic factors are also discussed. Recommendations are provided for patient follow-up after different therapeutic options. Conclusions These guidelines contain information for the diagnosis and treatment of individual patients according to a current standardised approach. When determining the optimal treatment regimen, physicians must take into account each individual patient's specific clinical characteristics with regard to renal function including medical comorbidities, tumour location, grade and stage, and molecular marker status.
-
european guidelines for the diagnosis and management of upper Urinary Tract urothelial cell carcinomas 2011 update
European Urology, 2011Co-Authors: Morgan Roupret, Richard Zigeuner, Joan Palou, Andreas Boehle, E Kaasinen, Richard Sylvester, Marko Babjuk, Willem OosterlinckAbstract:Context: The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper Urinary Tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective: This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition: The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: Urinary Tract Cancer, urothelial carcinomas, upper Urinary Tract, carcinoma, transitional cell, renal pelvis, ureter, bladder Cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references.
Hugh A Mostafid - One of the best experts on this subject based on the ideXlab platform.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, R Sylvester, Richard Zigeuner, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) guidelines panel on upper Urinary Tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, Richard Zigeuner, Richard Sylvester, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; ureteroscopy; nephroureterectomy; adjuvant treatment; instillation; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing number of retrospective articles in UTUC. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification, as well as for radical and conservative treatment; prognostic factors are also discussed. A single postoperative dose of intravesical mitomycin after radical nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumours and two functional kidneys. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis; appropriate diagnosis and management is most important. We present recommendations based on current evidence for optimal management.
Marko Babjuk - One of the best experts on this subject based on the ideXlab platform.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, R Sylvester, Richard Zigeuner, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) guidelines panel on upper Urinary Tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, Richard Zigeuner, Richard Sylvester, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; ureteroscopy; nephroureterectomy; adjuvant treatment; instillation; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing number of retrospective articles in UTUC. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification, as well as for radical and conservative treatment; prognostic factors are also discussed. A single postoperative dose of intravesical mitomycin after radical nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumours and two functional kidneys. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis; appropriate diagnosis and management is most important. We present recommendations based on current evidence for optimal management.
-
european guidelines for the diagnosis and management of upper Urinary Tract urothelial cell carcinomas 2011 update
Actas Urologicas Espanolas, 2012Co-Authors: Morgan Roupret, Richard Zigeuner, Joan Palou, Andreas Boehle, E Kaasinen, Richard Sylvester, Marko Babjuk, Willem OosterlinckAbstract:AbsTract Context The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper Urinary Tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: Urinary Tract Cancer, urothelial carcinomas, upper Urinary Tract, carcinoma, transitional cell, renal pelvis, ureter, bladder Cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references. Evidence synthesis There is a lack of data in the current literature to provide strong recommendations due to the rarity of the disease. A number of recent multicentre studies are now available, whereas earlier publications were based only on limited populations. However, most of these studies have been retrospective analyses. The 2009 TNM classification is recommended. Recommendations are given for diagnosis as well as for radical and conservative treatment; prognostic factors are also discussed. Recommendations are provided for patient follow-up after different therapeutic options. Conclusions These guidelines contain information for the diagnosis and treatment of individual patients according to a current standardised approach. When determining the optimal treatment regimen, physicians must take into account each individual patient's specific clinical characteristics with regard to renal function including medical comorbidities, tumour location, grade and stage, and molecular marker status.
-
european guidelines for the diagnosis and management of upper Urinary Tract urothelial cell carcinomas 2011 update
European Urology, 2011Co-Authors: Morgan Roupret, Richard Zigeuner, Joan Palou, Andreas Boehle, E Kaasinen, Richard Sylvester, Marko Babjuk, Willem OosterlinckAbstract:Context: The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper Urinary Tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective: This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition: The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: Urinary Tract Cancer, urothelial carcinomas, upper Urinary Tract, carcinoma, transitional cell, renal pelvis, ureter, bladder Cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references.
Richard Zigeuner - One of the best experts on this subject based on the ideXlab platform.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, R Sylvester, Richard Zigeuner, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) guidelines panel on upper Urinary Tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, Richard Zigeuner, Richard Sylvester, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; ureteroscopy; nephroureterectomy; adjuvant treatment; instillation; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing number of retrospective articles in UTUC. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification, as well as for radical and conservative treatment; prognostic factors are also discussed. A single postoperative dose of intravesical mitomycin after radical nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumours and two functional kidneys. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis; appropriate diagnosis and management is most important. We present recommendations based on current evidence for optimal management.
-
european guidelines for the diagnosis and management of upper Urinary Tract urothelial cell carcinomas 2011 update
Actas Urologicas Espanolas, 2012Co-Authors: Morgan Roupret, Richard Zigeuner, Joan Palou, Andreas Boehle, E Kaasinen, Richard Sylvester, Marko Babjuk, Willem OosterlinckAbstract:AbsTract Context The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper Urinary Tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: Urinary Tract Cancer, urothelial carcinomas, upper Urinary Tract, carcinoma, transitional cell, renal pelvis, ureter, bladder Cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references. Evidence synthesis There is a lack of data in the current literature to provide strong recommendations due to the rarity of the disease. A number of recent multicentre studies are now available, whereas earlier publications were based only on limited populations. However, most of these studies have been retrospective analyses. The 2009 TNM classification is recommended. Recommendations are given for diagnosis as well as for radical and conservative treatment; prognostic factors are also discussed. Recommendations are provided for patient follow-up after different therapeutic options. Conclusions These guidelines contain information for the diagnosis and treatment of individual patients according to a current standardised approach. When determining the optimal treatment regimen, physicians must take into account each individual patient's specific clinical characteristics with regard to renal function including medical comorbidities, tumour location, grade and stage, and molecular marker status.
-
european guidelines for the diagnosis and management of upper Urinary Tract urothelial cell carcinomas 2011 update
European Urology, 2011Co-Authors: Morgan Roupret, Richard Zigeuner, Joan Palou, Andreas Boehle, E Kaasinen, Richard Sylvester, Marko Babjuk, Willem OosterlinckAbstract:Context: The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper Urinary Tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective: This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition: The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: Urinary Tract Cancer, urothelial carcinomas, upper Urinary Tract, carcinoma, transitional cell, renal pelvis, ureter, bladder Cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references.
Eva Comperat - One of the best experts on this subject based on the ideXlab platform.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, Richard Zigeuner, Richard Sylvester, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; ureteroscopy; nephroureterectomy; adjuvant treatment; instillation; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing number of retrospective articles in UTUC. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification, as well as for radical and conservative treatment; prognostic factors are also discussed. A single postoperative dose of intravesical mitomycin after radical nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumours and two functional kidneys. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis; appropriate diagnosis and management is most important. We present recommendations based on current evidence for optimal management.
-
european association of urology guidelines on upper Urinary Tract urothelial cell carcinoma 2015 update
European Urology, 2015Co-Authors: Morgan Roupret, R Sylvester, Richard Zigeuner, Marko Babjuk, Eva Comperat, Maximilian Burger, Nigel C Cowan, Paolo Gontero, Bas W G Van Rhijn, Hugh A MostafidAbstract:AbsTract Context The European Association of Urology (EAU) guidelines panel on upper Urinary Tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. Objective To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: Urinary Tract Cancer; urothelial carcinomas; upper Urinary Tract, carcinoma; renal pelvis; ureter; bladder Cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts. Evidence synthesis Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies. Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper Urinary Tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
-
bladder recurrence after surgery for upper Urinary Tract urothelial cell carcinoma frequency risk factors and surveillance
Urologic Oncology-seminars and Original Investigations, 2011Co-Authors: Mariedominique Azemar, Eva Comperat, Francois Richard, Olivier Cussenot, Morgan RoupretAbstract:AbsTract Objective To highlight the main risk factors for metachronous bladder recurrence after treatment of an upper Urinary Tract urothelial cell carcinomas (UUT-UCCs) based on the recent literature. Materials and methods Data on urothelial malignancies after UUT-UCCs management in the literature were searched using MEDLINE and by matching the following key words: Urinary Tract Cancer; bladder carcinomas, urothelial carcinomas, upper Urinary Tract, renal pelvis, ureter prognosis, carcinoma, transitional cell, renal pelvis, ureter, bladder Cancer, cystectomy, nephroureterectomy, minimally invasive surgery, recurrence, and survival. Results No evidence level 1 information from prospective randomized trials was available. A range of 15% to 50% of patients with a UUT-UCC will subsequently develop a metachronous bladder UCC. Intraluminal tumor seeding and pan-urothelial field change effect have both been proposed to explain intravesical recurrences. In most cases, bladder Cancer arises in the first 2 years after UUT-UCC management. However the risk is lifelong and repeat episodes are common. The identification of variables that allow accurate risk stratification of UUT-UCC patients with regards to future bladder relapse is disappointing. No factors have been identified to date that can reliably predict bladder recurrences. A history of bladder Cancer prior to UUT-UCC management and upper Tract tumor multifocality are the only frequently reported clinical risk factors among current literature. Conclusion Prior histories of bladder Cancer and upper Tract tumor multifocality are the most frequently reported risk factors for bladder tumors following UUT-UCCs. Surveillance regimen is based on cystoscopy and on Urinary cytology for at least 5 years.
